GTAC
Research type
Research Study
Full title
Genomic Translation for ALS Clinical Care (GTAC)
IRAS ID
207319
Contact name
Siddharthan Chandran
Contact email
Clinicaltrials.gov Identifier
Duration of Study in the UK
2 years, 3 months, 27 days
Research summary
"Precision medicine" in Amyotrophic Lateral Sclerosis/Motor Neurone Disease,(ALS/MND) holds the promise of using a patient's genetic information to explain why ALS occurred, predict how it will progress, and ultimately select treatments that will best stop or even reverse the disease. This is an observational study following participants for up to three years. Total international recruitment is 1500 with the UK sites recruiting 50 to 80 participants per year,150 to 240 over duration of study. During this time, we will carefully define how MND presents and progresses in these subjects. In parallel, we will sequence their entire genomes and study that information in conjunction with gene expression levels form their blood cells. From these studies, we hope to better understand the role of genetics and gene expression in causing MND and to be able to more accurately classify MND patients for improved clinical trials. Finally our study will also create a large library of patient blood cells that can be transformed into neurones with stem-cell technologies. These cells will allow us to study the genetic factors we discover in greater detail and provide an invaluable resource to the MND research community.
REC name
South East Scotland REC 02
REC reference
16/SS/0211
Date of REC Opinion
20 Dec 2016
REC opinion
Further Information Favourable Opinion